Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort

[1]  Rosa M. Estrada-Y.-Martin,et al.  Clinical and genetic factors predictive of mortality in early systemic sclerosis. , 2009, Arthritis and rheumatism.

[2]  M. Mayes,et al.  Primary Biliary Cirrhosis (PBC), PBC Autoantibodies, and Hepatic Parameter Abnormalities in a Large Population of Systemic Sclerosis Patients , 2009, The Journal of Rheumatology.

[3]  P. Legmann,et al.  Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases , 2009, European Respiratory Journal.

[4]  R. Elashoff,et al.  Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma , 2009, The Journal of Rheumatology.

[5]  E. Savarino,et al.  Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. , 2009, American journal of respiratory and critical care medicine.

[6]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[7]  F. Mendoza,et al.  Systemic Sclerosis Mortality in the United States: 1999–2002 Implications for Patient Care , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  P. Merkel,et al.  Systemic sclerosis - continuing progress in developing clinical measures of response. , 2007, The Journal of rheumatology.

[9]  N. Goel,et al.  Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. , 2007, Arthritis and rheumatism.

[10]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[11]  H. Moutsopoulos,et al.  Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. , 2006, Arthritis and rheumatism.

[12]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[13]  B. Tilley,et al.  Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. , 2005, The Journal of rheumatology.

[14]  J. Hankinson,et al.  Standardisation of the single-breath determination of carbon monoxide uptake in the lung , 2005, European Respiratory Journal.

[15]  G. Viegi,et al.  Standardisation of the measurement of lung volumes , 2005, European Respiratory Journal.

[16]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[17]  A. Wells,et al.  Evaluation and management of alveolitis and interstitial lung disease in scleroderma , 2003, Current opinion in rheumatology.

[18]  A. Silman,et al.  Predictors of end stage lung disease in a cohort of patients with scleroderma , 2003, Annals of the rheumatic diseases.

[19]  M. Fujimoto,et al.  Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. , 2001, Arthritis and rheumatism.

[20]  J. Reveille,et al.  Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. , 2001, Seminars in arthritis and rheumatism.

[21]  A. Silman,et al.  A disease severity scale for systemic sclerosis: development and testing. , 1999, The Journal of rheumatology.

[22]  K. Flaherty,et al.  African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. , 1998, Chest.

[23]  A. Wiik,et al.  A longitudinal study of pulmonary function in Danish patients with systemic sclerosis , 1997, Clinical Rheumatology.

[24]  J. Reveille,et al.  Autoantibodies to fibrillarin in systemic sclerosis (scleroderma). An immunogenetic, serologic, and clinical analysis. , 1996, Arthritis and rheumatism.

[25]  Richard W. Martin,et al.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.

[26]  T. Medsger,et al.  Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.

[27]  P. Lachenbruch,et al.  Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis. , 1994, Chest.

[28]  T. Medsger,et al.  Autoantibody Reactive with RNA Polymerase III in Systemic Sclerosis , 1993, Annals of Internal Medicine.

[29]  T. Revenson,et al.  Coping with rheumatoid arthritis. , 1993, Bailliere's clinical rheumatology.

[30]  M. Abramson,et al.  Lung function abnormalities and decline of spirometry in scleroderma: an overrated danger? , 1991, Postgraduate medical journal.

[31]  Francis J. Keefe,et al.  Coping with rheumatoid arthritis pain: catastrophizing as a maladaptive strategy , 1989, Pain.

[32]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[33]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[34]  D. Furst,et al.  Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. , 1987, The American journal of medicine.

[35]  T. Medsger,et al.  Pulmonary involvement in systemic sclerosis (scleroderma). , 1985, Arthritis and rheumatism.

[36]  M. Hochberg,et al.  Clinical and Demographic Predictors of Loss of Pulmonary Function in Systemic Sclerosis , 1984, Medicine.

[37]  G. Hughes,et al.  Serological markers in progressive systemic sclerosis: clinical correlations. , 1983, Annals of the rheumatic diseases.

[38]  M. Hochberg,et al.  Serial pulmonary function in systemic sclerosis. , 1982, The American journal of medicine.

[39]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[40]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[41]  M. H. Williams,et al.  Serial changes in scleroderma and idiopathic interstitial lung disease. , 1973, Archives of internal medicine.

[42]  J. Cotes,et al.  Iron-deficiency anaemia: its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise. , 1972, Clinical science.

[43]  I. Fajardy,et al.  Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. , 2009, Arthritis and rheumatism.

[44]  D. Furst,et al.  Systemic Sclerosis Mortality in the United States: 1979–1998 , 2005, European Journal of Epidemiology.

[45]  J. Ioannidis,et al.  Mortality in systemic sclerosis: an international meta-analysis of individual patient data. , 2005, The American journal of medicine.

[46]  J. Vaqué,et al.  Mortality and prognostic factors in Spanish patients with systemic sclerosis. , 2003, Rheumatology.

[47]  V. Steen,et al.  Autoantibodies in systemic sclerosis. , 1996, Bulletin on the rheumatic diseases.

[48]  D. Sommers,et al.  A longitudinal analysis , 1992 .